Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

16 Apr 2009 08:49

RNS Number : 6591Q
ViaLogy PLC
16 April 2009
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

VIALOGY BEGINS DRILLING SECOND WELL AT TEXAS PROSPECT

Analysis started on third, deeper well

LondonApril 16th 2009ViaLogy PLC (LSE:VIY) announces that a rig has been sited on Atascosa Exploration LLC's Galba Prospect in south central Texas using QuantumRD™, ViaLogy's proprietary active signal processing technology that brings greater accuracy to seismic data analysis. Deployment of the rig and drilling of a second well is expected to start immediately. QuantumRD's processing and interpretation of site-specific 3D seismic data has determined optimal drill location, reservoir boundaries, hydrocarbon porosity, and other parameters for the new well. Results should be available within a week following drilling start. Under its contract with Atascosa ViaLogy is to receive 5% Back-In- After-Payout (BIAPO) Working Interest on oil production from the well.

 

This second project follows the successful QuantumRD positioning in March 2009 of a first well at Galba, named Cindy Bartlett #2.

ViaLogy also announces that it has commenced a QuantumRD analysis to determine the exact reservoir characteristics, porosity, and optimal extraction location for a third well on the Galba Prospect, this one in the Escondido sand formation. At considerably greater depth than its predecessors, the Escondido well should demonstrate QuantumRD's applicability for varying geologic formations at increasing depths and complex structural characteristics. Drilling on the Escondido well is planned for Q2 2009. 

Further, Vialogy announces that it has begun technical and business discussions with a large Texas-based exploration and production firm to apply its QuantumRD technology to that firm's exploration prospects. 

"QuantumRD's accurate predictions of reservoir boundaries and porosities on the Cindy Bartlett #2 well have confirmed our belief, shared by Atascosa, that we can substantially improve the current ratio that for every 10 on-shore drilling efforts in the US only four are successful," said Robert W. Dean, CEO of ViaLogy. "Our hope is that as QuantumRD's successes grow it will earn a reputation as a must-have tool in the exploration industry."

For further information please contact:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756)

Atascosa Exploration LLC  

John D. Mullins, CEO (+1 210-402-3656) 

Nominated Advisor to ViaLogy PLC (Seymour Pierce)  

Mark Percy +44 (0) 20-7107-8000

Broker to ViaLogy PLC (St. Helen's Capital)

Ruari McGirr / Sebastian Wykeham +44 (0) 207 628 5582 

About ViaLogy: 

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DRLGUUGCCUPBUMQ
Date   Source Headline
11th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
11th Jul 20239:33 amRNSForm 8.5 (EPT/RI) - Yourgene Health PLC
10th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
10th Jul 202311:44 amRNSForm 8.3 - Yourgene Health plc
10th Jul 202311:10 amRNSForm 8.3 - Yourgene
10th Jul 202310:10 amRNSForm 8.5 (EPT/RI)
10th Jul 20238:21 amRNSForm 8.3 - Yourgene Health PLC
7th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
7th Jul 202311:40 amRNSForm 8.5 (EPT/RI)
6th Jul 20232:00 pmRNSForm 8.3 - Yourgene Health plc
6th Jul 20231:00 pmRNSForm 8.5 (EPT/RI) - Replacement
6th Jul 202312:01 pmRNSForm 8.5 (EPT/RI)
6th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
6th Jul 20237:00 amRNSForm 8.3 - Yourgene Health PLC
5th Jul 20234:04 pmRNSForm 8.3 - Yourgene Health plc
5th Jul 20233:46 pmRNSFORM 8.3 - Yourgene Health Plc
5th Jul 20232:03 pmRNSForm 8.3 - Yourgene Health plc
5th Jul 20231:27 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc Amended
5th Jul 202312:30 pmRNSForm 8.3 - Yourgene Health Plc
5th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
5th Jul 202311:22 amRNSForm 8.3 - Yourgene Health plc
5th Jul 202311:03 amRNSForm 8.3 - YOURGENE HEALTH PLC
5th Jul 202310:33 amRNSForm 8.3 - Yourgene Health PLC
5th Jul 202310:23 amRNSForm 8.5 (EPT/RI)
4th Jul 20236:28 pmRNSForm 8.3 - Yourgene Health PLC
4th Jul 20235:41 pmRNSForm 8.3 -Yourgene Health plc
4th Jul 20234:53 pmRNSForm 8.3 - YourGene Health Plc
4th Jul 20233:57 pmRNSForm 8.3 - Yourgene Health plc
4th Jul 20232:26 pmRNSForm 8.3 - Yourgene Health plc
4th Jul 20231:56 pmRNSForm 8.3 - Yourgene Health plc
4th Jul 20231:56 pmRNSHolding(s) in Company
4th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
4th Jul 202311:57 amRNSForm 8.5 (EPT/RI)
4th Jul 20238:50 amRNSForm 8.3 - Yourgene Health PLC
3rd Jul 20234:04 pmRNSForm 8.3 - Yourgene Health PLC
3rd Jul 20237:00 amRNSRule 2.7 Announcement
13th Jun 20238:30 amRNSConditional disposal of Taiwan laboratory
6th Jun 202310:21 amRNSHolding(s) in Company
22nd May 20237:01 amRNSYGS to support MHC’s Boots agreement
22nd May 20237:00 amRNSDirectorate Change
5th May 202310:14 amRNSHolding(s) in Company
2nd May 20231:11 pmRNSHolding(s) in Company
27th Apr 20237:00 amRNSFull year unaudited trading update
18th Apr 20234:07 pmRNSHolding(s) in Company
31st Mar 20234:08 pmRNSHolding(s) in Company
24th Mar 20234:57 pmRNSHolding(s) in Company
17th Mar 20237:00 amRNSDirectorate Change
13th Mar 20237:00 amRNSStatement re. Silicon Valley Bank
21st Feb 202312:00 pmRNSChange of Website
27th Jan 20237:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.